Back to top

Myasthenia Gravis Network (MGNet) Pilot Grant Clinical Research Funding Announcement

Objectives

MGNet, a NIH-funded Rare Diseases Clinical Research Consortium (RDCRC) in partnership with the Myasthenia Gravis Foundation of America and Conquer MG, is seeking proposals for highly innovative investigations in early stages of development. The priorities of the Pilot Grant Program are:

  1. Identification treatment responsive biomarkers (please see Focus On Biomarkers Research)
  2. Assess clinical measures and improve that enhance clinical trial readiness
  3. Evaluation of therapeutic interventions for one or more of the five distinct sub-types of MG (additional information in the full proposal will be required for clinical trials).

Pilot studies must be designed to access the resources of MGNet and focused on clinical research, including fulfilling the definition of clinical research and exclusion of animal studies.

Funding

The MGNet expects to fund up to two grants, each at a level of $75,000 (IDCs will be limited to 10% and included in the $75,000). Projects will be funded for 12 months, with a start date of June 2022. Selection among the applications received will be based on the recommendations of a review committee. A grant may be renewed for an additional one year with approval by the same review process and availability of funds. Demonstration of fulfillment of initial aims and justification for additional funding will be required. The request will be required a minimum of three months prior to the initial funding period completion.

Eligibility

The PI must hold an MD, PhD, MD/PhD, RN or more advanced, PharmD, DDS, DVM, or equivalent and be a faculty member at an academic institution.

Please visit https://www.rarediseasesnetwork.org/mgnet/pilot  for more information and to submit applications.
Contact MGNet@gwu.edu with any questions.

Letter of Intent Due on December 17, 2021